朋友手工转录吉利德公司领导英文回答记者提问.
Q: Recently there was some reporting that China's Wuhan Virology Institute together with the Chinese Military Academy, they applied for the patent of Remdesivir. So obviously this is a delicate balance between fighting the epidemic, saving lives, vs IP protection question. So it's a little bit probably delicate. But I do want to know what is Gilead's reaction to the application and what's Gilead's stance if China's IP authority approves this application, and how we're going to continue to manage the control of Remdesivir development and also retaining the right to help fighting the epidemic.
A: Thank you so much. It's a very relevant question. And obviously it just came out overnight, and like everything with regard to Remdesivir, ah, you know we are moving as quickly as we can. I think my message to you and everybody is that has no impact on what we are going to do with global health. I just want to be tremendously clear here that our responsibility is the patients. And our responsibility is number one: pursue the right clinical programs to determine whether or not this medicine has impact with patients or not, and it'll be driven by the science, by the clinical evidence. And at the same time, ramping our production up, in the event that it does, we can get this medicine to as many patients around the globe as needed. Patent is not at the forefront of our minds. I will say, ‘cause I checked with our patent colleagues, that as we would with any medicine at Gilead, we have patents on Remdesivir, not only for the compound, but also for all of its use including coronavirus in regions around the world. But we will not get into a patent dispute, we will find a way to help patients, and of course, we will protect our intellectual property as a separate step of the process. But patients first.
(Applause.)
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
